Injectable Phase II
TrialWire™ AI-Match Platform was engaged by the sponsor at the recommendation of a regional CRO.
We were involved from start-up and worked alongside the CRO and 16 sites in Australia and New Zealand to deliver patients.
All patent engagement activity was funneled through the AI-Match so patients could be quickly online screened and connected to their nearest site for follow-up.
In addition, we outreached to PAGs to leverage databases and websites to share the AI-Match screener link.
AI-Match recruited 490 patients and the study was completed on time within budget.